Rebecca Garris Selected Research

Therapeutics

9/2022	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
1/2021	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
1/2021	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
1/2019	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
12/2018	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
3/2017	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
11/2015	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
5/2015	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
12/2014	Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
8/2010	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rebecca Garris Research Topics

Disease

26	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2022 - 08/2010
23	Philadelphia Chromosome 09/2022 - 08/2010
6	Pathologic Complete Response 01/2019 - 09/2010
5	Residual Neoplasm 02/2018 - 12/2014
3	Infections 12/2018 - 11/2015
2	Exanthema (Rash) 12/2018 - 11/2015
2	Pancreatitis 12/2018 - 11/2015
2	Hypertension (High Blood Pressure) 12/2018 - 11/2015
2	Myocardial Infarction 12/2018 - 11/2015
2	Hemorrhage 12/2018 - 12/2015
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2018 - 06/2015
1	Disease Progression 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Neoplasms (Cancer) 10/2017
1	Chromosome Aberrations (Chromosome Abnormalities) 03/2017
1	Pericardial Effusion 12/2015
1	Mucositis 06/2015
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2014
1	Blast Crisis (Blast Phase) 03/2014
1	Hypotension (Low Blood Pressure) 08/2013
1	Fever (Fevers) 08/2013

Drug/Important Bio-Agent (IBA)

10	Tyrosine Kinase InhibitorsIBA 09/2022 - 08/2013
10	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 08/2010
7	Dasatinib (BMS 354825)FDA Link 05/2022 - 09/2010
7	Inotuzumab OzogamicinIBA 01/2022 - 08/2013
5	blinatumomabIBA 09/2022 - 10/2018
5	ponatinibIBA 05/2022 - 11/2015
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 08/2010
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 08/2010
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 08/2010
4	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 09/2010
4	Prednisone (Sone)FDA LinkGeneric 12/2018 - 09/2010
3	Transaminases (Aminotransferases)IBA 12/2018 - 12/2015
2	Rituximab (Mabthera)FDA Link 01/2021 - 08/2010
2	BilirubinIBA 12/2018 - 08/2013
2	Methotrexate (Mexate)FDA LinkGeneric 02/2016 - 01/2016
2	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2016 - 01/2016
2	Monoclonal AntibodiesIBA 08/2013 - 08/2010
1	ofatumumab FDA Link 01/2021
1	CreatinineIBA 12/2018
1	nelarabine (506U78)FDA Link 01/2018
1	Proteins (Proteins, Gene)FDA Link 10/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2015
1	Alanine Transaminase (SGPT)IBA 11/2015
1	Everolimus FDA Link 06/2015

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 01/2021 - 08/2010
10	Therapeutics 09/2022 - 08/2010
2	Salvage Therapy 01/2021 - 01/2020
2	Consolidation Chemotherapy 01/2020 - 01/2018
2	Stem Cell Transplantation 02/2018 - 01/2016
1	Combination Drug Therapy (Combination Chemotherapy) 01/2019